



The roles of lipid and glucose metabolism in modulation of β -amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease

Naoyuki Sato^{1,2*} and Ryuichi Morishita¹

¹ Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Suita, Japan, ² Department of Geriatric Medicine, Graduate School of Medicine, Osaka University, Suita, Japan

Diabetes is a risk factor for Alzheimer disease (AD). Apolipoprotein E (ApoE) and several genes related to AD have recently been identified by genome-wide association studies (GWAS) as being closely linked to lipid metabolism. Lipid metabolism and glucose-energy metabolism are closely related. Here, we review the emerging evidence regarding the roles of lipid and glucose metabolism in the modulation of β -amyloid, tau, and neurodegeneration during the pathogenesis of AD. Disruption of homeostasis of lipid and glucose metabolism affects production and clearance of β -amyloid and tau phosphorylation, and induces neurodegeneration. A more integrated understanding of the interactions among lipid, glucose, and protein metabolism is required to elucidate the pathogenesis of AD and to develop next-generation therapeutic options.

Keywords: cholesterol, diabetes, A β , tau, neurodegeneration

OPEN ACCESS

Edited by:

Roxana Octavia Carare,
University of Southampton, UK

Reviewed by:

Emmanuel Planel,
Centre Hospitalier de l'Université
Laval, Canada
Ramesh Kandimalla,
Texas Tech University, USA

*Correspondence:

Naoyuki Sato
nsato@cgt.med.osaka-u.ac.jp

Received: 14 June 2015

Accepted: 04 October 2015


Published: 23 October 2015

Citation:

Sato N and Morishita R (2015) The roles of lipid and glucose metabolism in modulation of β -amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease. *Front. Aging Neurosci.* 7:199. doi: 10.3389/fnagi.2015.00199

INTRODUCTION

Alzheimer disease (AD) is a progressive neurodegenerative disorder that is pathologically characterized by cerebral atrophy (particularly within the hippocampus and temporal and parietal lobes), senile plaques, neurofibrillary tangles (NFT), and neuronal cell death. Familial AD is caused by mutations in the amyloid precursor protein (Goate et al., 1991) and presenilin (Sherrington et al., 1995). These mutations cause overproduction of β -amyloid (A β), particularly its longer form, A β 42, which aggregates *in vitro* (Jarrett et al., 1993) and forms the initial deposits in the brain (Iwatsubo et al., 1994) to form senile plaques. Apolipoprotein E (ApoE) is an essential regulator of brain cholesterol metabolism and is the strongest genetic risk factor for sporadic AD (Ashford, 2004). In addition to the ApoE gene, recent genome-wide association studies (GWAS) have identified novel risk genes for AD (Hollingsworth et al., 2011; Olgiati et al., 2011), and some of these genes are closely associated with lipid metabolism. Moreover, numerous epidemiological studies have demonstrated that patients with diabetes in which glucose-energy metabolism is affected have a significantly higher risk of developing AD (Ott et al., 1999; Kopf and Frölich, 2009; Maher and Schubert, 2009; Matsuzaki et al., 2010). However, the roles of lipid metabolism and glucose-energy metabolism in the pathogenesis of AD are not fully understood (**Figure 1**). Here, we review the roles of lipid and glucose metabolism in modulating A β , tau, and neurodegeneration during the pathogenesis of AD (**Table 1**) and focus on novel therapy development.



THE ROLE OF LIPID METABOLISM IN β -AMYLOID MODULATION

ApoE is an essential regulator of cholesterol metabolism and is the strongest genetic risk factor for AD (Ashford, 2004). The ApoE ϵ 4 allele increases the accumulation of senile plaques in patients with AD and in cognitively normal people (Reiman et al., 2009; Morris et al., 2010). Physiologically, ApoE is important for brain function through lipid transport of high-density lipoprotein-like particles (Raber et al., 2000; Ji et al., 2003; Bu, 2009; Filippini et al., 2009; Trachtenberg et al., 2011; Verghese et al., 2011; Wisdom et al., 2011). ApoE isoforms are believed to differentially regulate A β aggregation and uptake, degradation, and phagocytic clearance in the brain, and each isoform has distinct functions in regulating brain lipid transport, glucose metabolism, and mitochondrial function (Koistinaho et al., 2004; Verghese et al., 2013).

Moreover, independently of ApoE ϵ 4, high levels of low-density lipoprotein cholesterol and low levels of high-density lipoprotein cholesterol are associated with higher amyloid-PET indices (Reed et al., 2014). This observation may be partially explained by an *in vitro* experiment in which transient membrane cholesterol loading increased A β 42 secretion (Marquer et al., 2014). Interestingly, lipids also trigger the aggregation of α -synuclein, a major component of Lewy bodies, by stimulating nucleation (Galvagnion et al., 2015). This evidence increases the possibility that lipids might promote protein aggregation.

In addition to the ApoE gene, recent GWAS studies have identified novel risk genes for AD (Hollingworth et al., 2011; Olgiatei et al., 2011). These genes include bridging integrator 1 (BIN1), clusterin (CLU, also called apolipoprotein J), ATP-binding cassette transporter A7 (ABCA7), triggering receptor expressed on myeloid cells 2 (TREM2), and phosphatidylinositol-binding clathrin assembly protein (PICALM). CLU is a primary

brain cholesterol transport lipoprotein and may behave similarly to ApoE (Calero et al., 1999; Yu and Tan, 2012). ABCA7 is involved in lipid homeostasis (Tanaka et al., 2011b). Deletion of ABCA7 increases A β accumulation in amyloid precursor protein transgenic (APP Tg) mice through reduced phagocytic clearance of A β (Kim et al., 2013). TREM2 regulates the microglial response through lipid sensing around the senile plaque in an AD mouse model (Wang et al., 2015). BIN1 is involved in endocytosis and membrane trafficking (Itoh and De Camilli, 2006) through phosphatidylinositol binding (Lee et al., 2002; Kojima et al., 2004) and also modulates APP trafficking in neurons (Chapuis et al., 2013). BIN1 expression is also observed in microglia, suggesting a role for BIN1 in A β phagocytosis (Chapuis et al., 2013). PICALM also plays important roles in clathrin-mediated endocytosis (Dreyling et al., 1996) through phosphatidylinositol binding (Ford et al., 2001), suggesting involvement in APP trafficking (Xiao et al., 2012). Indeed, γ -secretase is endocytosed in a PICALM-dependent manner (Kanatsu et al., 2014). Interestingly, altering the rate of clathrin-mediated endocytosis of γ -secretase increases A β 42 production (Kanatsu et al., 2014). ApoE also could modulate γ -secretase cleavage of APP, though all three isoforms of ϵ 2, ϵ 3, and ϵ 4, have similar effects (Irizarry et al., 2004). Recent whole-exome sequencing and functional data indicate that carriers of PLD3 (phospholipase D3) coding variants have a two-fold increased risk for late-onset AD and that PLD3 influences APP processing (Cruchaga et al., 2014).

Although clinical studies have indicated that statins have no beneficial effect on cognitive function (McGuinness et al., 2014), statins administered in midlife might prevent AD in late life by modifying the genetic and non-genetic risk factors for AD (Sato et al., 2012; Shinohara et al., 2014). In experimental settings *in vivo* and *in vitro*, statins reduced the A β level in the brain

TABLE 1 | Lipid and glucose metabolism are associated with the modulation of β -amyloid and tau and neurodegeneration.

		A β		Tau	Neurodegeneration/ dementia	
		APP/A β trafficking/cleavage	A β clearance			
			Degradation /uptake	Phagocytic clearance		
Lipid Metabolism	Cholesterol	+; Marquer et al., 2014; Reed et al., 2014			+; Michikawa, 2006; Ohm and Meske, 2006; Maccioni et al., 2010; Glöckner and Ohm, 2014; Shibuya et al., 2015	+; Saher and Stumpf, 2015
	APOE	+; Irizarry et al., 2004	+; Verghese et al., 2013	+; Koistinaho et al., 2004	+; Ohm et al., 1999	+; Belinson et al., 2008
	BIN1	+; Itoh and De Camilli, 2006		+; Chapuis et al., 2013	+; Chapuis et al., 2013; Tan et al., 2013; Holler et al., 2014; Zhou et al., 2014	
	CLU		+; Yu and Tan, 2012			
	ABCA7			+; Kim et al., 2013		
	PICALM	+; Kanatsu et al., 2014				
	TREM2			+; Wang et al., 2015		
	PLD3	+; Cruchaga et al., 2014				
	LRP1		+; Kanekiyo et al., 2013; Ramanathan et al., 2015			
	Statin	+; Shinohara et al., 2010	+; Shinohara et al., 2010	+; Tanaka et al., 2011a,b	+; Boimel et al., 2009; Lu et al., 2010	
GLUCOSE Metabolism	Diabetes				+; Liu et al., 2009; Sato and Morishita, 2014	+; Sato and Morishita, 2014
	Glucose	+; Macauley et al., 2015				+; Sato and Morishita, 2014; Zhu et al., 2014; Weinstein et al., 2015; Winkler et al., 2015
	Insulin		+; Vekrellis et al., 2000; Shiiki et al., 2004		+; Starks et al., 2015	
	AMPK				+; Mairet-Coello et al., 2013	+; Mairet-Coello et al., 2013
	GSK3 β				+; Hanger et al., 1992; Yang et al., 1993	
	Pioglitazone		+; Mandrekar-Colucci et al., 2012	+; Mandrekar-Colucci et al., 2012		+; Heneka et al., 2015
	Metformin				+; Kickstein et al., 2010	+; Moore et al., 2013; Ng et al., 2014

(Fassbender et al., 2001; Burns et al., 2006; Ostrowski et al., 2007; Kurinami et al., 2008; Papadopoulos et al., 2014). A β reduction by a statin is associated with a reduction in the carboxyl terminal fragment of amyloid precursor protein (APP-CTF; Shinohara et al., 2010). Statins reduce the brain A β levels by increasing APP-CTF trafficking through isoprenylation inhibition. Moreover, a statin up-regulated A β clearance by up-regulating low-density lipoprotein receptor-related protein 1 (LRP1) expression in the vasculature (Shinohara et al., 2010). LRP1 play roles in the efflux of A β from the brain (Ramanathan et al., 2015) and neuronal A β uptake and degradation (Kanekiyo et al., 2013). Finally, statins enhance ABCA7-dependent phagocytosis (Tanaka et al., 2011a). Thus, lipid metabolism is involved in modulating A β levels.

THE ROLE OF LIPID METABOLISM IN TAU MODULATION

Normal tau promotes the assembly and stabilization of microtubules. However, hyperphosphorylated tau sequesters normal tau and disrupts microtubules, forming NFT (Iqbal et al., 1994, 2009). In mice expressing mutant human tau, cellular cholesterol levels were higher in neurons affected by tau pathology (Glöckner and Ohm, 2014). Indeed, impaired cholesterol metabolism is involved in tau hyperphosphorylation (Michikawa, 2006; Ohm and Meske, 2006; Maccioni et al., 2010). Emerging data suggest that BIN1 modulates tau pathology in addition to A β (Chapuis et al., 2013; Tan et al., 2013; Holler et al., 2014; Zhou et al., 2014). BIN co-localizes and interacts with tau

(Chapuis et al., 2013; Zhou et al., 2014). Therefore, BIN1 levels may correlate with NFTs in AD (Glennon et al., 2013; Holler et al., 2014). In addition to their effects on A β metabolism, statins suppress tau hyperphosphorylation induced by excess cholesterol in the brain (Lu et al., 2010) and also reduce NFTs in a tau pathology model (Boimel et al., 2009). Moreover, inhibition of cholesterol metabolism by blocking acyl-coenzyme A:cholesterol acyltransferase 1 activity reduces the amount of mutant human tau in neurons of triple transgenic mice (Shibuya et al., 2015). In comparison with ApoE ϵ 3, the presence of the ApoE ϵ 4 is reported to be associated with NFT formation (Ohm et al., 1999). These studies demonstrate that the regulation and dysregulation of cholesterol metabolism affect tau pathology in the brain.

THE ROLE OF LIPID METABOLISM IN NEURODEGENERATION MODULATION

As the largest pool of cholesterol resides in neuronal myelin membranes, disorders that impair sterol synthesis or intracellular trafficking of lipids in neurons cause hypomyelination and neurodegeneration (Saher and Stumpf, 2015). Glial lipid droplets induced by mitochondrial defects also promote neurodegeneration (Liu et al., 2015) suggesting a role for lipid metabolism in glial cells in neurodegeneration. Moreover, the human cortex demonstrates membrane protein oxidation (Granold et al., 2015) and altered phospholipid components during aging (Norris et al., 2015). Other than AD, impaired lipid metabolism has been reported in several neurodegenerative diseases. The huntingtin gene, which is causative for Huntington disease, also seems to play a regulatory role in lipid metabolism (Leoni and Caccia, 2015). Cholesterol metabolism impairment is proportion to the CAG repeat length and to the load of mutant huntingtin leading to neurodegeneration (Leoni and Caccia, 2015). Mucopolysaccharidosis III type C, a progressive neurological pediatric disease, is caused by mutations in the heparan- α -glucosaminide N-acetyltransferase gene and leads to a deficiency in acetyl-CoA: α -glucosaminide N-acetyltransferase (Martins et al., 2015). These results further support the role of lipid metabolism in neurodegeneration. Although reversible, statins might transiently impair cognitive function, especially during the initial administration to patients older than 75 years (Orsi et al., 2001; King et al., 2003; Wagstaff et al., 2003). This effect is probably due in part to cholesterol's modulation of NMDA receptor function (Korinek et al., 2015). Finally, activation of A β cascade in ApoE ϵ 4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits (Belinson et al., 2008). Taken together, these reports indicate that cholesterol metabolism is tightly linked to neurodegeneration.

THE ROLE OF GLUCOSE-ENERGY METABOLISM IN β -AMYLOID MODULATION

Diabetes in midlife is associated with mild cognitive impairment (MCI; Roberts et al., 2014), and impaired glycemia increases the

disease progression to dementia in patients with MCI (Morris et al., 2014). However, the mechanisms by which diabetes modifies cognitive function remain unclear (Sato and Morishita, 2013a,b). Diabetes seems to alter brain structure and function through A β /tau-dependent and independent mechanisms (Sato and Morishita, 2014). Insulin resistance in midlife is associated with neurodegeneration surrounding senile plaques (Matsuzaki et al., 2010), though retrospective studies suggest that the magnitude of senile plaques is comparable between AD with and without diabetes (Kalaria, 2009). Several groups reported that a high-fat diet causes A β accumulation in the brains of wild type rabbits (Sparks et al., 1994) and APP Tg mice (Refolo et al., 2000; Ho et al., 2004). In a murine model of AD, inducing acute hyperglycemia increases A β production (Macauley et al., 2015). Moreover, altering insulin and insulin signaling may change A β levels in the brain through proteolysis by insulin-degrading enzymes (Vekrellis et al., 2000) and/or A β clearance from the brain (Shiiki et al., 2004). Alternative mechanisms might include the accumulation of autophagosomes to enhance amyloidogenic APP processing (Son et al., 2012) or up-regulation of BACE1 (Guglielmotto et al., 2012). APP⁺-*ob/ob* mice, generated by crossing diabetic *ob/ob* mice, display increased A β deposition in the cerebral vasculature (Takeda et al., 2010). Whether glycogen synthase kinase-3(GSK3) controls APP processing and A β levels in brain is intriguing (Phiel et al., 2003; Sereno et al., 2009; Sofola et al., 2010), but controversial (Jaworski et al., 2011). Anti-diabetic drug, pioglitazone, stimulated A β degradation by both microglia and astrocytes in ApoE-dependent manner (Mandrekar-Colucci et al., 2012). Thus, glucose metabolism is also involved in modulating A β levels.

THE ROLE OF GLUCOSE-ENERGY METABOLISM IN TAU MODULATION

Several neuropathological studies suggest that the magnitude of NFTs in the brain at autopsy is not different between AD patients with and without diabetes (Kalaria, 2009). However, one report suggests that insulin resistance is associated with higher tau levels in the cerebrospinal fluid (Starks et al., 2015). Moreover, animal studies show that tau phosphorylation is increased in diabetes (Clodfelder-Miller et al., 2006; Jolivald et al., 2008; Ke et al., 2009; Kim et al., 2009; Qu et al., 2011). For example, tau phosphorylation is increased in *db/db* mice (Kim et al., 2009), streptozotocin-treated wild type mice (Clodfelder-Miller et al., 2006; Jolivald et al., 2008; Qu et al., 2011), and mutant human tau mice (Ke et al., 2009). Importantly, in humans, tau phosphorylation sites observed in AD are also increased in the diabetic brain (Liu et al., 2009). Conversely, CSF tau predicts changes in brain glucose metabolism, in turn causing longitudinal cognitive changes (Dowling et al., 2015). An energy-sensor, AMP-activated kinase (AMPK) activation is increased in the AD brain and AMPK phosphorylates Tau (Mairet-Coello et al., 2013). GSK3 also induces tau phosphorylation (Hanger et al., 1992; Yang et al., 1993). Anti-diabetic drug, metformin induces protein phosphatase 2A activity and reduces tau phosphorylation *in vitro* and in animal models (Kickstein

et al., 2010). Therefore, glucose-energy metabolism is closely related to modulation of tau.

THE ROLE OF GLUCOSE-ENERGY METABOLISM IN NEURODEGENERATION MODULATION

Diabetes causes structural deficits in the brain (Sato and Morishita, 2014) indicating that glucose-energy metabolism modulates neurodegeneration. Even in young adults, hyperglycemia is associated with subtle brain injury and impaired attention and memory (Weinstein et al., 2015). Indeed, diabetes reduces the volume of the hippocampus (Moran et al., 2013; Roberts et al., 2014), gray (García-Casares et al., 2014) and white matter (Moran et al., 2013). Gray matter loss occurs in the temporal, anterior cingulate, and frontal lobes (Moran et al., 2013; García-Casares et al., 2014; Roberts et al., 2014; Erus et al., 2015), while white matter loss appears in the frontal and temporal regions (Moran et al., 2013). In patients with AD, gray matter loss occurs in the temporal lobe, hippocampus, entorhinal and parietal lobes (Braak and Braak, 1991; Thompson et al., 2003; Andrade-Moraes et al., 2013), and white matter loss occurs in the temporal region (Mann, 1991). These studies indicate that diabetes causes neurodegeneration in the frontal and temporal lobes and other regions (Sato and Morishita, 2014). The molecular mechanism by which diabetes modulates neurodegeneration has not been fully elucidated, though several possible mechanisms have been proposed. Disturbance of glucose metabolism by GLUT1 deficiency causes neurodegeneration in APP Tg mice (Winkler et al., 2015). Another link between glucose hypometabolism and the progression of AD is the O-GlcNAcylation of proteins (Zhu et al., 2014). Decreased O-GlcNAcylation occurs in AD, which suggests that glucose hypometabolism may impair the protective roles of O-GlcNAc in neurons and lead to neurodegeneration (Zhu et al., 2014). AMPK is an energy-sensor, and AMPK over-activation is sufficient to cause dendritic spine loss (Mairet-Coello et al., 2013). Disturbed

mTOR signaling affected by glucose-energy metabolism also causes neurodegeneration through mitochondrial dysfunction and autophagy (Perluigi et al., 2015). An observational study suggests that pioglitazone treatment is associated with a reduced dementia risk in diabetes patients (Heneka et al., 2015). Metformin is also reported to reduce the risk of cognitive decline in diabetes patients (Ng et al., 2014), though other group showed an opposite effect (Moore et al., 2013). These studies indicate that the molecular mechanism by which the dysregulation of glucose-energy metabolism causes neurodegeneration should be targeted to develop novel dementia therapies.

SUMMARY

Recent large, long-term, randomized controlled trials suggest that a multidisciplinary intervention, including exercise and diet, could improve or maintain cognitive function in at-risk elderly people (Ngandu et al., 2015). Exercise and diet alter glucose and lipid metabolism in subjects. As reviewed here, disruption of homeostasis of lipid and glucose metabolism affects production and clearance of β -amyloid and tau phosphorylation, and induces neurodegeneration. Therefore, a more integrated understanding of the interactions among lipid, glucose, and protein metabolism will be required to elucidate the pathogenesis of AD and to develop next-generation therapeutic options.

ACKNOWLEDGMENTS

This work was supported in part by grants-in-aid from Japan Promotion of Science; the Japanese Ministry of Education, Culture, Sports, Science and Technology and the Japan Science and Technology Agency (MEXT26293167 and MEXT15K15272 to NS); a Takeda Science Foundation Research Encouragement Grant; a SENSHIN Medical Research Foundation Research Grant; a Novartis Foundation for Gerontological Research Award; and an annual research award grant from the Japanese Society of Anti-aging Medicine (to NS).

REFERENCES

- Andrade-Moraes, C. H., Oliveira-Pinto, A. V., Castro-Fonseca, E., da Silva, C. G., Guimaraes, D. M., Szczupak, D., et al. (2013). Cell number changes in Alzheimer's disease relate to dementia, not to plaques and tangles. *Brain* 136, 3738–3752. doi: 10.1093/brain/awt273
- Ashford, J. W. (2004). APOE genotype effects on Alzheimer's disease onset and epidemiology. *J. Mol. Neurosci.* 23, 157–165. doi: 10.1385/JMN:23:3:157
- Belinson, H., Lev, D., Masliah, E., and Michaelson, D. M. (2008). Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits. *J. Neurosci.* 28, 4690–4701. doi: 10.1523/JNEUROSCI.5633-07.2008
- Boimel, M., Grigoriadis, N., Lourbopoulos, A., Touloumi, O., Rosenmann, D., Abramsky, O., et al. (2009). Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. *J. Neuropathol. Exp. Neurol.* 68, 314–325. doi: 10.1097/NEN.0b013e31819ac3cb
- Braak, H., and Braak, E. (1991). Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol.* 82, 239–259. doi: 10.1007/BF00308809
- Bu, G. (2009). Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. *Nat. Rev. Neurosci.* 10, 333–344. doi: 10.1038/nrn2620
- Burns, M. P., Igbavboa, U., Wang, L., Wood, W. G., and Duff, K. (2006). Cholesterol distribution, not total levels, correlate with altered amyloid precursor protein processing in statin-treated mice. *Neuromolecular Med.* 8, 319–328. doi: 10.1385/NMM:8:3:319
- Calero, M., Tokuda, T., Rostagno, A., Kumar, A., Zlokovic, B., Frangione, B., et al. (1999). Functional and structural properties of lipid-associated apolipoprotein J (clusterin). *Biochem. J.* 344(Pt 2), 375–383. doi: 10.1042/bj3440375
- Chapuis, J., Hansmannel, F., Gistelinc, M., Mounier, A., Van Cauwenberghe, C., Kolen, K. V., et al. (2013). Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. *Mol. Psychiatry* 18, 1225–1234. doi: 10.1038/mp.2013.1
- Clodfelder-Miller, B. J., Zmijewska, A. A., Johnson, G. V., and Jope, R. S. (2006). Tau is hyperphosphorylated at multiple sites in mouse brain *in vivo* after streptozotocin-induced insulin deficiency. *Diabetes* 55, 3320–3325. doi: 10.2337/db06-0485

- Cruchaga, C., Karch, C. M., Jin, S. C., Benitez, B. A., Cai, Y., Guerreiro, R., et al. (2014). Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. *Nature* 505, 550–554. doi: 10.1038/nature12825
- Dowling, N. M., Johnson, S. C., Gleason, C. E., and Jagust, W. J. (2015). The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function. *Neuroimage* 105, 357–368. doi: 10.1016/j.neuroimage.2014.10.050
- Dreyling, M. H., Martinez-Climent, J. A., Zheng, M., Mao, J., Rowley, J. D., and Bohlander, S. K. (1996). The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family. *Proc. Natl. Acad. Sci. U.S.A.* 93, 4804–4809. doi: 10.1073/pnas.93.10.4804
- Erus, G., Battapady, H., Zhang, T., Lovato, J., Miller, M. E., Williamson, J. D., et al. (2015). Spatial patterns of structural brain changes in type 2 diabetic patients and their longitudinal progression with intensive control of blood glucose. *Diabetes Care* 38, 97–104. doi: 10.2337/dc14-1196
- Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., Keller, P., et al. (2001). Simvastatin strongly reduces levels of Alzheimer's disease β -amyloid peptides A β 42 and A β 40 *in vitro* and *in vivo*. *Proc. Natl. Acad. Sci. U.S.A.* 98, 5856–5861. doi: 10.1073/pnas.081620098
- Filippini, N., MacIntosh, B. J., Hough, M. G., Goodwin, G. M., Frisoni, G. B., Smith, S. M., et al. (2009). Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. *Proc. Natl. Acad. Sci. U.S.A.* 106, 7209–7214. doi: 10.1073/pnas.0811879106
- Ford, M. G., Pearse, B. M., Higgins, M. K., Vallis, Y., Owen, D. J., Gibson, A., et al. (2001). Simultaneous binding of PtdIns(4,5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes. *Science* 291, 1051–1055. doi: 10.1126/science.291.5506.1051
- Galvagnion, C., Buell, A. K., Meisl, G., Michaels, T. C., Vendruscolo, M., Knowles, T. P., et al. (2015). Lipid vesicles trigger α -synuclein aggregation by stimulating primary nucleation. *Nat. Chem. Biol.* 11, 229–234. doi: 10.1038/nchembio.1750
- García-Casares, N., Berthier, M. L., Jorge, R. E., Gonzalez-Alegre, P., Gutiérrez-Cardo, A., Ríojas Villodres, J., et al. (2014). Structural and functional brain changes in middle-aged type 2 diabetic patients: a cross-sectional study. *J. Alzheimers Dis.* 40, 375–386. doi: 10.3233/JAD-131736
- Glennon, E. B., Whitehouse, I. J., Miners, J. S., Kehoe, P. G., Love, S., Kellett, K. A., et al. (2013). BIN1 is decreased in sporadic but not familial Alzheimer's disease or in aging. *PLoS ONE* 8:e78806. doi: 10.1371/journal.pone.0078806
- Glöckner, F., and Ohm, T. G. (2014). Tau pathology induces intraneuronal cholesterol accumulation. *J. Neuropathol. Exp. Neurol.* 73, 846–854. doi: 10.1097/NEN.0000000000000103
- Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L., et al. (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature* 349, 704–706. doi: 10.1038/349704a0
- Granold, M., Moosmann, B., Staib-Laszczik, I., Arendt, T., Del Rey, A., Engelhard, K., et al. (2015). High membrane protein oxidation in the human cerebral cortex. *Redox Biol.* 4, 200–207. doi: 10.1016/j.redox.2014.12.013
- Guglielmo, M., Aragno, M., Tamagno, E., Vercellinatto, I., Visentin, S., Medana, C., et al. (2012). AGEs/RAGE complex upregulates BACE1 via NF- κ B pathway activation. *Neurobiol. Aging* 33, 196.e13–196.e27. doi: 10.1016/j.neurobiolaging.2010.05.026
- Hanger, D. P., Hughes, K., Woodgett, J. R., Brion, J. P., and Anderton, B. H. (1992). Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. *Neurosci. Lett.* 147, 58–62. doi: 10.1016/0304-3940(92)90774-2
- Heneka, M. T., Fink, A., and Doblhammer, G. (2015). Effect of pioglitazone medication on the incidence of dementia. *Ann. Neurol.* 78, 284–294. doi: 10.1002/ana.24439
- Ho, L., Qin, W., Pompl, P. N., Xiang, Z., Wang, J., Zhao, Z., et al. (2004). Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. *FASEB J.* 18, 902–904. doi: 10.1096/fj.03-0978fe
- Holler, C. J., Davis, P. R., Beckett, T. L., Platt, T. L., Webb, R. L., Head, E., et al. (2014). Bridging integrator 1 (BIN1) protein expression increases in the Alzheimer's disease brain and correlates with neurofibrillary tangle pathology. *J. Alzheimers Dis.* 42, 1221–1227. doi: 10.3233/JAD-132450
- Hollingworth, P., Harold, D., Sims, R., Gerrish, A., Lambert, J. C., Carrasquillo, M. M., et al. (2011). Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat. Genet.* 43, 429–435. doi: 10.1038/ng.803
- Iqbal, K., Alonso, A. C., Gong, C. X., Khatoon, S., Singh, T. J., and Grundke-Iqbal, I. (1994). Mechanism of neurofibrillary degeneration in Alzheimer's disease. *Mol. Neurobiol.* 9, 119–123. doi: 10.1007/BF02816111
- Iqbal, K., Liu, F., Gong, C. X., Alonso Adel, C., and Grundke-Iqbal, I. (2009). Mechanisms of tau-induced neurodegeneration. *Acta Neuropathol.* 118, 53–69. doi: 10.1007/s00401-009-0486-3
- Irizarry, M. C., Deng, A., Lleo, A., Berezovska, O., Von Arnim, C. A., Martin-Rehrmann, M., et al. (2004). Apolipoprotein E modulates γ -secretase cleavage of the amyloid precursor protein. *J. Neurochem.* 90, 1132–1143. doi: 10.1111/j.1471-4159.2004.02581.x
- Itoh, T., and De Camilli, P. (2006). BAR, F-BAR (EFC) and ENTH/ANTH domains in the regulation of membrane-cytosol interfaces and membrane curvature. *Biochim. Biophys. Acta* 1761, 897–912. doi: 10.1016/j.bbali.2006.06.015
- Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., and Ihara, Y. (1994). Visualization of A β 42(43) and A β 40 in senile plaques with end-specific A β monoclonals: evidence that an initially deposited species is A β 42(43). *Neuron* 13, 45–53. doi: 10.1016/0896-6273(94)90458-8
- Jarrett, J. T., Berger, E. P., and Lansbury, P. T. Jr. (1993). The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. *Biochemistry* 32, 4693–4697. doi: 10.1021/bi00069a001
- Jaworski, T., Dewachter, I., Lechat, B., Gees, M., Kremer, A., Demedts, D., et al. (2011). GSK-3 α/β kinases and amyloid production *in vivo*. *Nature* 480, E4–E5. discussion: E6. doi: 10.1038/nature10615
- Ji, Y., Gong, Y., Gan, W., Beach, T., Holtzman, D. M., and Wisniewski, T. (2003). Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patients. *Neuroscience* 122, 305–315. doi: 10.1016/j.neuroscience.2003.08.007
- Jolival, C. G., Lee, C. A., Beiswenger, K. K., Smith, J. L., Orlov, M., Torrance, M. A., et al. (2008). Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. *J. Neurosci. Res.* 86, 3265–3274. doi: 10.1002/jnr.21787
- Kalaria, R. N. (2009). Neurodegenerative disease: diabetes, microvascular pathology and Alzheimer disease. *Nat. Rev. Neurol.* 5, 305–306. doi: 10.1038/nrn.2009.72
- Kanatsu, K., Morohashi, Y., Suzuki, M., Kuroda, H., Watanabe, T., Tomita, T., et al. (2014). Decreased CALM expression reduces A β 42 to total A β ratio through clathrin-mediated endocytosis of γ -secretase. *Nat. Commun.* 5:3386. doi: 10.1038/ncomms4386
- Kanekiyo, T., Cirrito, J. R., Liu, C. C., Shinohara, M., Li, J., Schuler, D. R., et al. (2013). Neuronal clearance of amyloid- β by endocytic receptor LRP1. *J. Neurosci.* 33, 19276–19283. doi: 10.1523/JNEUROSCI.3487-13.2013
- Ke, Y. D., Delerue, F., Gladbach, A., Götz, J., and Ittner, L. M. (2009). Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. *PLoS ONE* 4:e7917. doi: 10.1371/journal.pone.0007917
- Kickstein, E., Krauss, S., Thornhill, P., Rutschow, D., Zeller, R., Sharkey, J., et al. (2010). Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. *Proc. Natl. Acad. Sci. U.S.A.* 107, 21830–21835. doi: 10.1073/pnas.0912793107
- Kim, B., Backus, C., Oh, S., Hayes, J. M., and Feldman, E. L. (2009). Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. *Endocrinology* 150, 5294–5301. doi: 10.1210/en.2009-0695
- Kim, W. S., Li, H., Ruberu, K., Chan, S., Elliott, D. A., Low, J. K., et al. (2013). Deletion of Abca7 increases cerebral amyloid- β accumulation in the J20 mouse model of Alzheimer's disease. *J. Neurosci.* 33, 4387–4394. doi: 10.1523/JNEUROSCI.4165-12.2013
- King, D. S., Wilburn, A. J., Wofford, M. R., Harrell, T. K., Lindley, B. J., and Jones, D. W. (2003). Cognitive impairment associated with atorvastatin and simvastatin. *Pharmacotherapy* 23, 1663–1667. doi: 10.1592/phco.23.15.1663.31953
- Koistinaho, M., Lin, S., Wu, X., Koger, D., Hanson, J., Higgs, R., et al. (2004). Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid- β peptides. *Nat. Med.* 10, 719–726. doi: 10.1038/nm1058

- Kojima, C., Hashimoto, A., Yabuta, I., Hirose, M., Hashimoto, S., Kanaho, Y., et al. (2004). Regulation of Bin1 SH3 domain binding by phosphoinositides. *EMBO J.* 23, 4413–4422. doi: 10.1038/sj.emboj.7600442
- Kopf, D., and Frölich, L. (2009). Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. *J. Alzheimers Dis.* 16, 677–685. doi: 10.3233/JAD-2009-1011
- Korinek, M., Vyklicky, V., Borovska, J., Lichnerova, K., Kaniakova, M., Krausova, B., et al. (2015). Cholesterol modulates open probability and desensitization of NMDA receptors. *J. Physiol.* 593, 2279–2293. doi: 10.1113/jphysiol.2014.288209
- Kurinami, H., Sato, N., Shinohara, M., Takeuchi, D., Takeda, S., Shimamura, M., et al. (2008). Prevention of amyloid β -induced memory impairment by fluvastatin, associated with the decrease in amyloid β accumulation and oxidative stress in amyloid β injection mouse model. *Int. J. Mol. Med.* 21, 531–537. doi: 10.3892/ijmm.21.5.531
- Lee, E., Marcucci, M., Daniell, L., Weisz, O. A., Ochoa, G. C., Farsad, K., et al. (2002). Amphiphysin 2 (Bin1) and T-tubule biogenesis in muscle. *Science* 297, 1193–1196. doi: 10.1126/science.1071362
- Leoni, V., and Caccia, C. (2015). The impairment of cholesterol metabolism in Huntington disease. *Biochim. Biophys. Acta* 1851, 1095–1105. doi: 10.1016/j.bbaliip.2014.12.018
- Liu, L., Zhang, K., Sandoval, H., Yamamoto, S., Jaiswal, M., Sanz, E., et al. (2015). Glial lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration. *Cell* 160, 177–190. doi: 10.1016/j.cell.2014.12.019
- Liu, Y., Liu, F., Grundke-Iqbal, I., Iqbal, K., and Gong, C. X. (2009). Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. *J. Neurochem.* 111, 242–249. doi: 10.1111/j.1471-4159.2009.06320.x
- Lu, F., Li, X., Suo, A. Q., and Zhang, J. W. (2010). Inhibition of tau hyperphosphorylation and β amyloid production in rat brain by oral administration of atorvastatin. *Chin. Med. J.* 123, 1864–1870.
- Macauley, S. L., Stanley, M., Caesar, E. E., Yamada, S. A., Raichle, M. E., Perez, R., et al. (2015). Hyperglycemia modulates extracellular amyloid- β concentrations and neuronal activity *in vivo*. *J. Clin. Invest.* 125, 2463–2467. doi: 10.1172/JCI79742
- Maccioni, R. B., Fariás, G., Morales, I., and Navarrete, L. (2010). The revitalized tau hypothesis on Alzheimer's disease. *Arch. Med. Res.* 41, 226–231. doi: 10.1016/j.arcmed.2010.03.007
- Maher, P. A., and Schubert, D. R. (2009). Metabolic links between diabetes and Alzheimer's disease. *Expert Rev. Neurother.* 9, 617–630. doi: 10.1586/ern.09.18
- Mairet-Coello, G., Courchet, J., Pieraut, S., Courchet, V., Maximov, A., and Polleux, F. (2013). The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of A β oligomers through Tau phosphorylation. *Neuron* 78, 94–108. doi: 10.1016/j.neuron.2013.02.003
- Mandrekar-Colucci, S., Karlo, J. C., and Landreth, G. E. (2012). Mechanisms underlying the rapid peroxisome proliferator-activated receptor- γ -mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. *J. Neurosci.* 32, 10117–10128. doi: 10.1523/JNEUROSCI.5268-11.2012
- Mann, D. M. (1991). The topographic distribution of brain atrophy in Alzheimer's disease. *Acta Neuropathol.* 83, 81–86. doi: 10.1007/BF00294434
- Marquer, C., Laine, J., Dauphinot, L., Hanbouch, L., Lemerrier-Neuillet, C., Pierrot, N., et al. (2014). Increasing membrane cholesterol of neurons in culture recapitulates Alzheimer's disease early phenotypes. *Mol. Neurodegener.* 9:60. doi: 10.1186/1750-1326-9-60
- Martins, C., Hulková, H., Dridi, L., Dormoy-Raclet, V., Grigoryeva, L., Choi, Y., et al. (2015). Neuroinflammation, mitochondrial defects and neurodegeneration in mucopolysaccharidosis III type C mouse model. *Brain* 138, 336–355. doi: 10.1093/brain/awu355
- Matsuzaki, T., Sasaki, K., Tanizaki, Y., Hata, J., Fujimi, K., Matsui, Y., et al. (2010). Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. *Neurology* 75, 764–770. doi: 10.1212/WNL.0b013e3181eee25f
- McGuinness, B., Craig, D., Bullock, R., Malouf, R., and Passmore, P. (2014). Statins for the treatment of dementia. *Cochrane Database Syst. Rev.* 7:CD007514. doi: 10.1002/14651858.cd007514.pub3
- Michikawa, M. (2006). Role of cholesterol in amyloid cascade: cholesterol-dependent modulation of tau phosphorylation and mitochondrial function. *Acta Neurol. Scand. Suppl.* 185, 21–26. doi: 10.1111/j.1600-0404.2006.00681.x
- Moore, E. M., Mander, A. G., Ames, D., Kotowicz, M. A., Carne, R. P., Brodaty, H., et al. (2013). Increased risk of cognitive impairment in patients with diabetes is associated with metformin. *Diabetes Care* 36, 2981–2987. doi: 10.2337/dc13-0229
- Moran, C., Phan, T. G., Chen, J., Blizzard, L., Beare, R., Venn, A., et al. (2013). Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. *Diabetes Care* 36, 4036–4042. doi: 10.2337/dc13-0143
- Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., et al. (2010). APOE predicts amyloid- β but not tau Alzheimer pathology in cognitively normal aging. *Ann. Neurol.* 67, 122–131. doi: 10.1002/ana.21843
- Morris, J. K., Vidoni, E. D., Honea, R. A., and Burns, J. M. (2014). Impaired glycemia increases disease progression in mild cognitive impairment. *Neurobiol. Aging* 35, 585–589. doi: 10.1016/j.neurobiolaging.2013.09.033
- Ng, T. P., Feng, L., Yap, K. B., Lee, T. S., Tan, C. H., and Winblad, B. (2014). Long-term metformin usage and cognitive function among older adults with diabetes. *J. Alzheimers Dis.* 41, 61–68. doi: 10.3233/JAD-131901
- Ngandu, T., Lehtisalo, J., Solomon, A., Levälähti, E., Ahtiluoto, S., Antikainen, R., et al. (2015). A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. *Lancet* 385, 2255–2263. doi: 10.1016/S0140-6736(15)60461-5
- Norris, S. E., Friedrich, M. G., Mitchell, T. W., Truscott, R. J., and Else, P. L. (2015). Human prefrontal cortex phospholipids containing docosahexaenoic acid increase during normal adult aging, whereas those containing arachidonic acid decrease. *Neurobiol. Aging* 36, 1659–1669. doi: 10.1016/j.neurobiolaging.2015.01.002
- Ohm, T. G., and Meske, V. (2006). Cholesterol, statins and tau. *Acta Neurol. Scand. Suppl.* 185, 93–101. doi: 10.1111/j.1600-0404.2006.00692.x
- Ohm, T. G., Scharnagl, H., März, W., and Bohl, J. (1999). Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. *Acta Neuropathol.* 98, 273–280. doi: 10.1007/s004010051080
- Olgiati, P., Politis, A. M., Papadimitriou, G. N., De Ronchi, D., and Serretti, A. (2011). Genetics of late-onset Alzheimer's disease: update from the alzgene database and analysis of shared pathways. *Int. J. Alzheimers Dis.* 2011:832379. doi: 10.4061/2011/832379
- Orsi, A., Sherman, O., and Woldeselassie, Z. (2001). Simvastatin-associated memory loss. *Pharmacotherapy* 21, 767–769. doi: 10.1592/phco.21.7.767.34577
- Ostrowski, S. M., Wilkinson, B. L., Golde, T. E., and Landreth, G. (2007). Statins reduce amyloid- β production through inhibition of protein isoprenylation. *J. Biol. Chem.* 282, 26832–26844. doi: 10.1074/jbc.M702640200
- Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A., Hofman, A., and Breteler, M. M. (1999). Diabetes mellitus and the risk of dementia: the rotterdam study. *Neurology* 53, 1937–1942. doi: 10.1212/WNL.53.9.1937
- Papadopoulos, P., Tong, X. K., and Hamel, E. (2014). Selective benefits of simvastatin in bitransgenic APPSwe, Ind/TGF- β 1 mice. *Neurobiol. Aging* 35, 203–212. doi: 10.1016/j.neurobiolaging.2013.07.010
- Perluigi, M., Di Domenico, F., and Butterfield, D. A. (2015). mTOR signaling in aging and neurodegeneration: at the crossroad between metabolism dysfunction and impairment of autophagy. *Neurobiol. Dis.* doi: 10.1016/j.nbd.2015.03.014. [Epub ahead of print].
- Phiel, C. J., Wilson, C. A., Lee, V. M., and Klein, P. S. (2003). GSK-3 α regulates production of Alzheimer's disease amyloid- β peptides. *Nature* 423, 435–439. doi: 10.1038/nature01640
- Qu, Z., Jiao, Z., Sun, X., Zhao, Y., Ren, J., and Xu, G. (2011). Effects of streptozotocin-induced diabetes on tau phosphorylation in the rat brain. *Brain Res.* 1383, 300–306. doi: 10.1016/j.brainres.2011.01.084
- Raber, J., Wong, D., Yu, G. Q., Buttini, M., Mahley, R. W., Pitas, R. E., et al. (2000). Apolipoprotein E and cognitive performance. *Nature* 404, 352–354. doi: 10.1038/35006165

- Ramanathan, A., Nelson, A. R., Sagare, A. P., and Zlokovic, B. V. (2015). Impaired vascular-mediated clearance of brain amyloid β in Alzheimer's disease: the role, regulation and restoration of LRP1. *Front. Aging Neurosci.* 7:136. doi: 10.3389/fnagi.2015.00136
- Reed, B., Villeneuve, S., Mack, W., DeCarli, C., Chui, H. C., and Jagust, W. (2014). Associations between serum cholesterol levels and cerebral amyloidosis. *JAMA Neurol.* 71, 195–200. doi: 10.1001/jamaneurol.2013.5390
- Refolo, L. M., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint, G. S., et al. (2000). Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. *Neurobiol. Dis.* 7, 321–331. doi: 10.1006/nbdi.2000.0304
- Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., et al. (2009). Fibrillar amyloid- β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. *Proc. Natl. Acad. Sci. U.S.A.* 106, 6820–6825. doi: 10.1073/pnas.0900345106
- Roberts, R. O., Knopman, D. S., Przybelski, S. A., Mielke, M. M., Kantarci, K., Preboske, G. M., et al. (2014). Association of type 2 diabetes with brain atrophy and cognitive impairment. *Neurology* 82, 1132–1141. doi: 10.1212/WNL.0000000000000269
- Saher, G., and Stumpf, S. K. (2015). Cholesterol in myelin biogenesis and hypomyelinating disorders. *Biochim. Biophys. Acta* 1851, 1083–1094. doi: 10.1016/j.bbailip.2015.02.010
- Sato, N., and Morishita, R. (2013a). Plasma $\text{a}\beta$: a possible missing link between Alzheimer disease and diabetes. *Diabetes* 62, 1005–1006. doi: 10.2337/db12-1549
- Sato, N., and Morishita, R. (2013b). Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factors. *Front. Aging Neurosci.* 5:64. doi: 10.3389/fnagi.2013.00064
- Sato, N., and Morishita, R. (2014). Brain alterations and clinical symptoms of dementia in diabetes: $\text{a}\beta/\tau$ -dependent and independent mechanisms. *Front. Endocrinol. (Lausanne)* 5:143. doi: 10.3389/fendo.2014.00143
- Sato, N., Shinohara, M., Rakugi, H., and Morishita, R. (2012). Dual effects of statins on $\text{A}\beta$ metabolism: upregulation of the degradation of APP-CTF and $\text{A}\beta$ clearance. *Neurodegener. Dis.* 10, 305–308. doi: 10.1159/000334534
- Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., et al. (2009). A novel GSK-3 β inhibitor reduces Alzheimer's pathology and rescues neuronal loss *in vivo*. *Neurobiol. Dis.* 35, 359–367. doi: 10.1016/j.nbd.2009.05.025
- Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., et al. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature* 375, 754–760. doi: 10.1038/375754a0
- Shibuya, Y., Niu, Z., Bryleva, E. Y., Harris, B. T., Murphy, S. R., Kheirollah, A., et al. (2015). Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer's disease mouse and reduces human P301L-tau content at the presymptomatic stage. *Neurobiol. Aging* 36, 2248–2259. doi: 10.1016/j.neurobiolaging.2015.04.002
- Shiiki, T., Ohtsuki, S., Kurihara, A., Naganuma, H., Nishimura, K., Tachikawa, M., et al. (2004). Brain insulin impairs amyloid- β (1-40) clearance from the brain. *J. Neurosci.* 24, 9632–9637. doi: 10.1523/JNEUROSCI.2236-04.2004
- Shinohara, M., Sato, N., Kurinami, H., Takeuchi, D., Takeda, S., Shimamura, M., et al. (2010). Reduction of brain β -amyloid ($\text{A}\beta$) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and $\text{A}\beta$ clearance. *J. Biol. Chem.* 285, 22091–22102. doi: 10.1074/jbc.M110.102277
- Shinohara, M., Sato, N., Shimamura, M., Kurinami, H., Hamasaki, T., Chatterjee, A., et al. (2014). Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors. *Front. Aging Neurosci.* 6:71. doi: 10.3389/fnagi.2014.00071
- Sofola, O., Kerr, F., Rogers, I., Killick, R., Augustin, H., Gandy, C., et al. (2010). Inhibition of GSK-3 ameliorates $\text{A}\beta$ pathology in an adult-onset Drosophila model of Alzheimer's disease. *PLoS Genet.* 6:e1001087. doi: 10.1371/journal.pgen.1001087
- Son, S. M., Song, H., Byun, J., Park, K. S., Jang, H. C., Park, Y. J., et al. (2012). Accumulation of autophagosomes contributes to enhanced amyloidogenic APP processing under insulin-resistant conditions. *Autophagy* 8, 1842–1844. doi: 10.4161/aut.21861
- Sparks, D. L., Scheff, S. W., Hunsaker, J. C. III, Liu, H., Landers, T., and Gross, D. R. (1994). Induction of Alzheimer-like β -amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. *Exp. Neurol.* 126, 88–94. doi: 10.1006/exnr.1994.1044
- Starks, E. J., O'Grady, J. P., Hoscheidt, S. M., Racine, A. M., Carlsson, C. M., Zetterberg, H., et al. (2015). Insulin resistance is associated with higher cerebrospinal fluid tau levels in asymptomatic APOE ϵ 4 carriers. *J. Alzheimers Dis.* 46, 525–533. doi: 10.3233/JAD-150072
- Takeda, S., Sato, N., Uchio-Yamada, K., Sawada, K., Kunieda, T., Takeuchi, D., et al. (2010). Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and $\text{A}\beta$ deposition in an Alzheimer mouse model with diabetes. *Proc. Natl. Acad. Sci. U.S.A.* 107, 7036–7041. doi: 10.1073/pnas.1000645107
- Tan, M. S., Yu, J. T., and Tan, L. (2013). Bridging integrator 1 (BIN1): form, function, and Alzheimer's disease. *Trends Mol. Med.* 19, 594–603. doi: 10.1016/j.molmed.2013.06.004
- Tanaka, N., Abe-Dohmae, S., Iwamoto, N., Fitzgerald, M. L., and Yokoyama, S. (2011a). HMG-CoA reductase inhibitors enhance phagocytosis by upregulating ATP-binding cassette transporter A7. *Atherosclerosis* 217, 407–414. doi: 10.1016/j.atherosclerosis.2011.06.031
- Tanaka, N., Abe-Dohmae, S., Iwamoto, N., and Yokoyama, S. (2011b). Roles of ATP-binding cassette transporter A7 in cholesterol homeostasis and host defense system. *J. Atheroscler. Thromb.* 18, 274–281. doi: 10.5551/jat.6726
- Thompson, P. M., Hayashi, K. M., de Zubicaray, G., Janke, A. L., Rose, S. E., Semple, J., et al. (2003). Dynamics of gray matter loss in Alzheimer's disease. *J. Neurosci.* 23, 994–1005.
- Trachtenberg, A. J., Filippini, N., Cheeseman, J., Duff, E. P., Neville, M. J., Ebmeier, K. P., et al. (2011). The effects of APOE on brain activity do not simply reflect the risk of Alzheimer's disease. *Neurobiol. Aging* 33, 618.e1–618.e13. doi: 10.1016/j.neurobiolaging.2010.11.01
- Vekrellis, K., Ye, Z., Qiu, W. Q., Walsh, D., Hartley, D., Chesneau, V., et al. (2000). Neurons regulate extracellular levels of amyloid β -protein via proteolysis by insulin-degrading enzyme. *J. Neurosci.* 20, 1657–1665.
- Vergheze, P. B., Castellano, J. M., Garai, K., Wang, Y., Jiang, H., Shah, A., et al. (2013). ApoE influences amyloid- β ($\text{A}\beta$) clearance despite minimal apoE/ $\text{A}\beta$ association in physiological conditions. *Proc. Natl. Acad. Sci. U.S.A.* 110:E1807–E1816. doi: 10.1073/pnas.1220484110
- Vergheze, P. B., Castellano, J. M., and Holtzman, D. M. (2011). Apolipoprotein E in Alzheimer's disease and other neurological disorders. *Lancet Neurol.* 10, 241–252. doi: 10.1016/S1474-4422(10)70325-2
- Wagstaff, L. R., Mitton, M. W., Arvik, B. M., and Doraiswamy, P. M. (2003). Statin-associated memory loss: analysis of 60 case reports and review of the literature. *Pharmacotherapy* 23, 871–880. doi: 10.1592/phco.23.7.871.32720
- Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., et al. (2015). TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. *Cell* 160, 1061–1071. doi: 10.1016/j.cell.2015.01.049
- Weinstein, G., Maillard, P., Himali, J. J., Beiser, A. S., Au, R., Wolf, P. A., et al. (2015). Glucose indices are associated with cognitive and structural brain measures in young adults. *Neurology* 84, 2329–2337. doi: 10.1212/WNL.0000000000001655
- Winkler, E. A., Nishida, Y., Sagare, A. P., Rege, S. V., Bell, R. D., Perlmutter, D., et al. (2015). GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. *Nat. Neurosci.* 18, 521–530. doi: 10.1038/nn.3966
- Wisdom, N. M., Callahan, J. L., and Hawkins, K. A. (2011). The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis. *Neurobiol. Aging* 32, 63–74. doi: 10.1016/j.neurobiolaging.2009.02.003
- Xiao, Q., Gil, S. C., Yan, P., Wang, Y., Han, S., Gonzales, E., et al. (2012). Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis. *J. Biol. Chem.* 287, 21279–21289. doi: 10.1074/jbc.M111.338376
- Yang, S. D., Song, J. S., Yu, J. S., and Shiah, S. G. (1993). Protein kinase FA/GSK-3 phosphorylates tau on Ser²³⁵-Pro and Ser⁴⁰⁴-Pro that are abnormally phosphorylated in Alzheimer's disease brain. *J. Neurochem.* 61, 1742–1747. doi: 10.1111/j.1471-4159.1993.tb09811.x

- Yu, J. T., and Tan, L. (2012). The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy. *Mol. Neurobiol.* 45, 314–326. doi: 10.1007/s12035-012-8237-1
- Zhou, Y., Hayashi, I., Wong, J., Tugusheva, K., Renger, J. J., and Zerbinatti, C. (2014). Intracellular clusterin interacts with brain isoforms of the bridging integrator 1 and with the microtubule-associated protein Tau in Alzheimer's disease. *PLoS ONE* 9:e103187. doi: 10.1371/journal.pone.0103187
- Zhu, Y., Shan, X., Yuzwa, S. A., and Vocadlo, D. J. (2014). The emerging link between O-GlcNAc and Alzheimer disease. *J. Biol. Chem.* 289, 34472–34481. doi: 10.1074/jbc.R114.601351

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Sato and Morishita. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.